PCN22 Safety Profile of Bevacizumab in Metastatic Colorectal Cancer

Value in Health - United Kingdom
doi 10.1016/j.jval.2011.08.1123
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Effect and Safety of Bevacizumab-Containing Chemotherapy Treatment in Chinese Patients With Metastatic Colorectal Cancer

OncoTargets and Therapy
OncologyPharmacology
2013English

Critical Appraisal of Bevacizumab in the Treatment of Metastatic Colorectal Cancer

OncoTargets and Therapy
OncologyPharmacology
2012English

Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients

Frontiers in Oncology
Cancer ResearchOncology
2019English

Bevacizumab for Metastatic Colorectal Cancer: A Global Cost‐Effectiveness Analysis

Oncologist
Cancer ResearchMedicineOncology
2017English

Cediranib With mFOLFOX6 vs Bevacizumab With mFOLFOX6 in Previously Treated Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2013English

The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-Ras Mutation Status: Analysis of a Phase III Study of Bevacizumab With Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

Oncologist
Cancer ResearchMedicineOncology
2009English

Discontinuation of First-Line Bevacizumab in Metastatic Colorectal Cancer: The BEAWARE Italian Observational Study

Tumori
MedicineCancer ResearchOncology
2019English

Impact of Primary Tumour Location on Efficacy of Bevacizumab Plus Chemotherapy in Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

A Phase 2 Randomised Study of Veliparib Plus FOLFIRI±bevacizumab Versus Placebo Plus FOLFIRI±bevacizumab in Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy